16 Weeks of Progressive Barefoot Running Training Changes Impact Force and Muscle Activation in Habitual Shod Runners by Ana Paula da Silva Azevedo (3373688)

“…A 16-week progressive barefoot running training seems to be an effective training strategy to reduce impact force, improve shock attenuation and to decrease muscle activation intensity, not only in BF running, but also in SH running, although BF condition seems to be more influenced by BF training.…”

%-change after 3 and 12 months of hormone therapy in trans women and trans men. by Moya H. Schutte (12245290)

Subjects:

Frequency of sexual activity (A) and number of sexual partners (B) as a function of different levels of ED severity based on IIEF-5 score (22–25 without ED; 17–21 mild ED; 12–16 mi... by Mikolaj Przydacz (3621878)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

Scatterplot and line plot of predicted response for the 25^th, 50^th and 75th quantile for MCS in nonseminomas cases, on time between diagnosis and compilation... by Aleksandar Jovanovski (11529711)

Subjects:

Table_1_Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy.docx by Shuang Li (146392)

“…Genomic DNAs were extracted and 16S rRNA gene sequencing was performed. Microbiome diversity was significantly decreased in patients with acute and chronic HIV infections compared with those in controls at the sampling time of W0 and the significant difference remained at W12. …”

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Inflammation and hemostasis markers at 0, 3 and 12 months in trans men (absolute values). by Moya H. Schutte (12245290)

Subjects:

Image_1_IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.TIF by Renée H. Fiechter (10230473)

“…For some cell types this was even more pronounced at week 24, but clearly synovial inflammation was incompletely resolved. IL-17A and F, TNF, IL-6, IL-8, and IL-12p40 were not significantly downregulated in qPCR analysis of W12 total biopsies, only MMP3 and IL-23p19 were significantly decreased. …”

Reduced follicles, decreased ovulation and decreased fertilization of female Meox-2-cre/Separase S1121A mutant mice. by Juan Xu (225010)

Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…<p>(A) RFF is decreased by alterations in heart rate. …”

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Decreased macrophage recruitment correlates with decreased angiogenesis. by Johanna R. Reed (306158)

“…<p>A) Quantification of BrdU incorporation demonstrates that decreased macrophage infiltration does not significantly correlate with a change in epithelial cell proliferation (N.S. = not significant). …”

SDG decreases iron-induced apoptosis in H9c2 cells. by Stephanie Puukila (568109)

Numbers of all fractures occurring in men, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age. by Camilla Bergh (9904522)

“…<p>Numbers of all fractures occurring in men, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age.…”

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)